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The HBe Ag precursor is encoded by the 637-bp 
precore/core open reading frame starting at nucleotide 
1814 of the HBV minus strand genome (nomenclature 
according to Galibert et al [4]), The frequently 
described mutation is a G to A substitution at the 
3’ end of the pre-C gene (nucleotide 1896), which 
converts codon 28 for tryptophan (TGG) to a termina- 
tion codon (TAG) [S], resulting in the failure of HBe - . . . - - .. - . 
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Chronic infection with hepatitis B virus (HBV) leads 
to a wide spectrum of liver diseases, including asymp- 
tomatic carrier state, chronic active hepatitis, cirrhosis 
and hepatocellular carcinoma. Patients presenting with 
chronic active hepatitis typically have evidence of HBV 
replication marked by high levels of HBV DNA, HBV 
surface antigen (HBs Ag) and the e antigen (HBe Ag) 
in their serum [l]. In later stages of the disease, 
seroconversion from HBe Ag to anti-HBe antibody 
classically indicates a transition to a ‘non-replicative’ 
phase, in which necro-inflammatory activity ceases. In 
some cases, however, anti-HBe seroconversion is not 
followed by such a favorable outcome, and markers for 
HBV replication remain detectable [2]. Carman et a1 
[3] have studied such patients and found that they 
carried HBV mutants which cannot synthesize the 
precore precursor protein and therefore HBe Ag. 
Ag production and the cessation of its secretion into 
the bloodstream. It is often associated with a G to A 
silent mutation at nucleotide (nt) position 1899. The 
frequency of the nt 1896 mutation varies in different 
studies, ranging from 46% [6] to 80% [3]. This vari- 
ability led us to investigate the frequency of the nt 1896 
mutation and the presence of other putative mutations 
in a cohort of French patients. 
We analyzed 32 serum samples from chronically 
infected patients showing discordant serologic profiles, 
i.e. positive for HBs Ag and HBV DNA, negative for 
HBe Ag and positive for anti-HBe antibody. Serum 
samples were submitted to heat treatment (100 “C) for 
30 min and then clarified by centrifugation (12000g) 
for 30 min. This rapid technique for HBV DNA 
preparation had been validated in preliminary studies 
as compared either to classical proteinase K-sodium 
dodecylsulfate (SDS) lysis followed by phenol extraction 
or to NaOH treatment of the serum. We applied an 
amplification-created restriction site method derived 
from that described by Lindh et a1 [7] for detecting the 
nt 1896 G to A mutation. According to this procedure, 
the nt 1865-2058 region of HBV DNA was amplified 
using P1 primer with a mismatch at position 1893. 
When the nt 1896 G to A mutation was present, the 
194-bp P C R  product exhibited a BSU 361 restriction 
site which could be shown by enzyme digestion and 
agarose gel electrophoresis. Prior to hgestion, a plasmid 
containing a unique BSU 361 restriction site was 
added as a control for the completion of digestion. 
The specificity of the P C R  reaction was checked by 
hybridization with a digoxigenin-labeled probe specific 
for the HBV precore region. In parallel, the nt 
1728-2160 region of HBV DNA was amplified for 
the determination of nucleotide sequence using a T7 
polymerase sequencing kit (Pharmacia). 
After digestion with BSU 361, we observed three 
patterns of migration in an agarose gel among the 32 
samples tested. Five cases (16%) showed a digested 
product of 165 bp characteristic ofthe G to A mutation. 
Twenty cases (62%) showed an undigested PCR pro- 
duct of 194 bp. In seven (22%) cases, two fragments 
comigrated in the agarose gel, one of 194 bp, and one 
of 165 bp, corresponding to a mixed viral population 
(wild type and mutant). In these cases, the possibility 
of partial digestion with BSU 361 was ruled out by 
S h o r t  Communicat ions and Letters t o  t he  Edi tors  59 1 
checking the full activity of the enzyme on a control 
plasmid. In all cases tested, the direct sequencing of the 
PCR products confirmed the presence of the nt 1896 
G to A mutation detected by restriction assay. In 
addition, the G to A mutation at nt 1899 was also 
found, as previously reported by others. For the cases 
in which the nt 1896 G to A mutation was not 
detected, direct sequencing revealed several other 
mutations in the precore gene: A to G mutation at nt 
1838, A to T mutation at nt 1850, T to C mutation at  
nt 1858, and G to C mutation at nt 1862. None of 
these mutations could account for the absence of HBe 
Ag production, suggesting that this property was linked 
either to mutations in other parts of the HBV DNA 
genome or to other intracell mechanisms. Indeed, 
other mutations leading to HBe seroconversion have 
been described, either in the precore gene or in the 
precore promoter gene [8-101. 
Our results clearly confirm that the nt 1896 G to 
A mutation is not the unique pathway for the emer- 
gence of HBe antigen-negative mutants. In our series, 
this mutation accounts for only 32% of mutant cases, 
including the cases of mixed virus populations. Other 
mutations or other mechanisms need to be explored as 
well as the putative correlation between molecular 
findings and clinical patterns of chronic HBV infection. 
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